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Phase II Study of Celecoxib and Docetaxel in Non-small
Cell Lung Cancer (NSCLC) Patients with Progression after
Platinum-Based Therapy
Bryan J. Schneider, MD,* Gregory P. Kalemkerian, MD,* Michael J. Kraut, MD,†
Antoinette J. Wozniak, MD,† Francis P. Worden, MD,* Daryn W. Smith, MS,‡ Wei Chen, PhD,‡
and Shirish M. Gadgeel, MD†
Introduction: To evaluate the efficacy and toxicity of the combi-
nation of celecoxib and docetaxel in patients with advanced non-
small cell lung cancer after failure of platinum-based therapy.
Methods: Patients with relapsed non-small cell lung cancer received
celecoxib 400 mg orally twice daily beginning 7 days before the first
cycle of docetaxel and the celecoxib was continued with no inter-
ruption. Docetaxel 75 mg/m2 was administered intravenously on a
21-day cycle. The primary end point of the study was the 6-month
survival rate.
Results: Twenty-four patients were enrolled and twenty patients
were treated (median age 60, M:F 16:8). Most patients had a
baseline performance status of 1. The objective response rate was
10% (95% confidence interval CI, 0–25%) and the 6-month
survival rate was 59% (95% CI 37–80%). Median survival time was
6.9 months (95% CI, 2.8–15.2 months) and the 1- and 2-year
survival rates were 36% (95% CI, 15–57%) and 1% (95% CI,
0–10%), respectively. The most frequent grade 3 adverse events
were neutropenia (58%) and neutropenic fever (21%) which resulted
in early closure of the trial.
Conclusions: The addition of celecoxib to docetaxel did not seem to
improve the response rate and survival compared with docetaxel
alone. The combination demonstrated considerable neutropenia and
complications from febrile neutropenia that suggests celecoxib may
enhance the marrow toxicity of docetaxel.
Key Words: Non-small cell lung cancer, COX-2, Relapsed,
Docetaxel, Celecoxib.
(J Thorac Oncol. 2008;3: 1454–1459)
Each year in the United States over 200,000 new cases oflung cancer are diagnosed, most of which are non-small
cell lung carcinoma (NSCLC).1 Approximately 40% of pa-
tients present with metastatic disease and will only be can-
didates for palliative chemotherapy. Standard initial therapy
usually consists of a platinum-based drug regimen sometimes
with the addition of bevacizumab.2,3 However, with a median
progression free survival of 3 to 4 months, many patients are
candidates for subsequent therapy.
Docetaxel was the first agent approved for the treatment
of advanced NSCLC after the failure of initial platinum-based
therapy. Unfortunately, the response rate is only around 7%
with a 1-year survival rate of 32 to 37%.4,5 Efforts have been
made to use doublet therapy for platinum-refractory or re-
lapsed disease; however, toxicity has outweighed the clinical
benefit in this setting.6–9 More effective and better tolerated
therapy is needed for patients who progress after platinum-
based treatment.
Cyclooxygenase-2 (COX-2) is an inducible enzyme
that facilitates the conversion of arachidonic acid to prosta-
glandins involved in the regulation of normal growth re-
sponses, but has also been implicated in aberrant cellular
growth and angiogenesis.10,11 Prostaglandins derived from
COX-2 may stimulate oncogenesis through the inhibition of
immune surveillance and apoptosis in addition to the promo-
tion of angiogenesis and tumor invasion.12–17 Specifically,
COX-2 expression facilitates the formation of prostaglan-
din-E2 (PGE2) which promotes the production and release of
vascular endothelial growth factor, an angiogenic growth
factor.18 Overexpression of COX-2 has also been found to
increase production of the antiapoptotic proteins Bcl-2 and
surviving in lung cancer cell lines.19,20 Tumoral COX-2
mRNA expression has been associated with decreased sur-
vival and early relapses in patients with resected NSCLC.21
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Previous studies have demonstrated that approximately 70%
of NSCLCs overexpress COX-2 when compared with normal
lung tissue and given the involvement of COX-2 in facilitat-
ing tumor angiogenesis and inhibiting apoptosis of malignant
cells, it is an attractive target for cancer therapy.22,23
Preclinical studies utilizing COX-2 inhibitors have
demonstrated a direct antitumor effect in NSCLC models.24
The addition of a COX-2 inhibitor to taxane chemotherapy
might be beneficial as in vitro experiments have demonstrated
that taxanes induce COX-2 and subsequent prostaglandin
synthesis which may result in reduced effectiveness of the
chemotherapy.25 Indeed, in human NSCLC cell lines, do-
cetaxel plus the COX-2 inhibitor nimesulide demonstrated
improved cytotoxicity compared with single-agent taxane
therapy.26 With these considerations, we designed a phase II
study to evaluate the effectiveness and tolerability of do-
cetaxel plus celecoxib in patients with NSCLC who pro-
gressed after platinum-based chemotherapy.
PATIENTS AND METHODS
Eligibility
Patients with histologically or cytologically docu-
mented NSCLC were entered onto this study between No-
vember 2001 and May 2002. Patients were required to have
evidence of progressive or relapsed disease during or after
treatment with platinum-containing chemotherapy for stage
IIIA, IIIB or IV NSCLC. Chemotherapy, radiation therapy,
and major surgery were not allowed within 2 weeks of
starting celecoxib. In addition, any nonsteroidal antiinflam-
matory drug therapy must have been discontinued 30 days
before the initiation of treatment with the exception of 325
mg/d of aspirin for cardiovascular conditions. Other require-
ments included measurable or evaluable disease, age 18,
Zubrod performance status (PS) of 0–2, Absolute Neutrophil
Count (ANC) 1500/mm3, platelet count 100,000/mm3,
total bilirubin less than or equal to the institutional upper limit
of normal, serum glutamic-oxaloacetic transaminase 2.5X
the upper limit of normal and serum creatinine 1.5 mg/dL
(132.6 mol/L). Exclusion criteria also included an allergy to
sulfa drugs, prior therapy with docetaxel, body weight below
50 kg and symptomatic, uncontrolled brain or leptomeningeal
disease. Patients were ineligible if they had peripheral neu-
ropathy of grade2, a thromboembolic event within 4 weeks
of study entry, a history of gastrointestinal bleeding within 6
months of study entry or peptic ulcer disease of any duration.
The trial was approved by the local Institutional Review
Boards and written informed consent was obtained from all
patients.
Treatment
Patients were treated with celecoxib 400 mg adminis-
tered orally twice daily beginning 7 days before the first cycle
of docetaxel. Patients were asked to take each dose with a
meal. Docetaxel was administered at a dose of 75 mg/m2 and
was repeated every 21 days. Therapy continued until progres-
sion or unacceptable toxicity. Patients could be maintained on
celecoxib after discontinuation of docetaxel for reasons other
than disease progression. Each cycle was of 21 day duration
except the first cycle which lasted for 28 days as this cycle
included the 7-day induction of celecoxib before the first
docetaxel infusion.
Dose Adjustment for Toxicity
Full dose of docetaxel was delivered if the ANC
1500/mm3 and platelets 100,000/mm3 and nonhemato-
logic toxicity grade 1; but the dose of docetaxel was
reduced by 20% if the nadir ANC was 500/mm3 and/or the
nadir platelet count was 25,000/mm3. Docetaxel was de-
layed for ANC 1500/mm3 and/or platelets 100,000/mm3,
or grade 3 nonhematologic toxicity for a maximum of 2
weeks. If more than or equal to grade 3 nonhematologic
toxicity was observed at any point, then the dose of subse-
quent cycles of docetaxel was reduced by 20%. Docetaxel
could begin when toxicity resolved to les than or equal to
grade 1. Patients experiencing more than or equal to grade 3
neurotoxicity resulted in discontinuation of protocol therapy.
Grade 2 neurotoxicity resulted in a maximum delay of 2
weeks of docetaxel and a subsequent 20% dose reduction.
Celecoxib was not held or reduced for hematologic
toxicity, but was reduced to 300 mg orally twice daily for an
increase in serum creatinine between 50 and 100% of the
pretherapy value and was held for a serum creatinine 100%
of the pretherapy value. If the creatinine level recovered to
100% increase from pretherapy levels within a 2-week
period, then the dose was reduced to 300 mg twice daily for
all subsequent treatments. Celecoxib was also held for grade
3 nonhematologic toxicity and full dose therapy could
resume within a 2-week period if the toxicity resolved to
grade 1.
Assessment of Response and Toxicity
Patients were considered evaluable for toxicity assess-
ment if treatment with celecoxib was started and were eligible
for response if they received at least one dose of celecoxib
and docetaxel. Patients underwent appropriate scans to eval-
uate for response after every two cycles of treatment. Re-
sponse to therapy was assessed according to the Response
Evaluation Criteria in Solid Tumors criteria.27 Celecoxib and
docetaxel were discontinued if a patient developed progres-
sive disease or life-threatening/irreversible toxicity that was
not manageable with symptomatic care or dose reduction
and/or delay. All toxicity was graded according to the Na-
tional Cancer Institute Common Toxicity Criteria version 2.0
(http://ctep.cancer.gov/reporting/ctc.html).
Statistical Analyses
The primary objective of this study was to assess the
6-month survival rate in patients treated with the combination
of docetaxel and celecoxib. To minimize the number of
patients required for this study, a two-stage Minimax Simon’s
design was used.28 This drug combination would be consid-
ered not interesting if the 6-month survival rate is35%, and
it would be of definite clinical interest if the 6-month survival
rate is55%. With 21 patients in stage I and 39 total patients,
the 2-stage design used had a 5% type I error and 80% power
in testing the hypothesis. The trial was to be terminated at
stage I if 8 patients survived 6 months. A total of 39
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evaluable patients were to be accrued unless undue toxicity
warranted early termination of accrual.
To be evaluable for efficacy, the patient had to receive
at least one dose of celecoxib and one dose of docetaxel.
Other endpoints of this study were treatment toxicity, overall
survival duration, and time to treatment failure. Overall
survival (OS) was defined as the time from the initiation of
celecoxib treatment to death from any cause. Time to treat-
ment failure (TTF) was defined as the time from the initiation
of celecoxib treatment to the documentation of disease pro-
gression, death due to any cause, or early discontinuation of
therapy.
Descriptive analyses for baseline characteristics were
performed. Six-month survival rate and median survival were
conservatively estimated using Kaplan-Meier method with
linear interpolation due to the small sample size.29 Time to
event endpoints (OS and TTF) were plotted using Kaplan-
Meier curves.30 The SAS System (Cary, NC) was used for all
analyses.
RESULTS
Twenty-four patients were enrolled onto the study be-
tween November 2001 and December 2002. Accrual was
stopped after 24 patients since a high rate of neutropenic
fever was observed. Data were collected until May 12, 2004
when the last patient on study expired. Patient characteristics
are summarized in Table 1. The median age at study entry
was 60 years (range, 41–76), 67% were males. All patients
had received prior platinum-based chemotherapy and half of
the patients were deemed platinum refractory (progression
within 3 months of treatment). Eighteen patients had received
prior therapy with paclitaxel and 10 patients had received 2
prior regimens. The majority of patients had stage IV disease
(79%) and the rest had stage III disease. Sixty-seven percent
of the patients had a Zubrod PS of 0 or 1.
Toxicity
A median of 2 cycles were administered (range, 1–14).
Four patients (17%) began celecoxib but never received
docetaxel. One patient developed pneumonia, was hospital-
ized and died on day 26. Two patients had a severe decline in
PS due to progressive disease and were removed from study.
One patient received the celecoxib for 2 days and then
requested to be removed from study. Per protocol design,
these 4 patients were not evaluable for treatment response,
but were included in the toxicity assessment.
Toxicity data are listed in Table 2. The most common
grade 3–4 toxicities were neutropenia (58%) and neutropenic
fever (21%) and most of these patients required hospitaliza-
tion. When the 4 patients that had not received docetaxel
were excluded, the rates were 70% and 25%, respectively.
None developed grade 3–4 thrombocytopenia and only 2 had
grade 3 anemia. Six patients (25%) required at least one dose
reduction of docetaxel, 5 due to toxicity occurring during the
first cycle. Two other patients (8%) had a delay of treatment
by 1 week. No patient developed nonhematologic toxicity
requiring dose reduction of celecoxib. Twelve patients (50%)
required hospitalization during study treatment: 5 for neutro-
penic fever/sepsis, 4 for progressive dyspnea likely from
malignancy, 2 for new onset brain metastases and 1 for
nonneutropenic pneumonia.
Response and Survival
Two of the 20 evaluable patients had a partial response
to treatment (10%, 95% CI, 0–25%). Twelve patients had a
partial response or stable disease through 2 cycles of therapy
for a tumor control rate of 60% (95% CI 40–80%). The
6-month survival rate was 59% (95% CI 37–80%).
The median time to treatment failure was 1.67 months
(95% CI, 1.3–2.9). Median overall survival was 6.9 months
(95% CI, 2.8–15.2 months) and the 1- and 2-year survival
rates were 36% (95% CI, 15–57%) and 1% (95% CI,
0–10%), respectively. The intent to treat Kaplan-Meier esti-
TABLE 2. Worst Toxicity (Grade 3) Experienced per
Patient (n  24) Grade
Toxicity 3 4 5
Anemia 2 0 0
Neutropenia 6 8 0
Neutropenic fever 3 2 0
Nausea/vomiting 3 0 0
Neuropathy 1 0 0
Dyspnea 0 1 1
Pneumonia 0 0 1
Mucositis 1 0 0
Fatigue/decline in PS 2 2 0
PS, performance status.
TABLE 1. Patient Characteristics
Characteristic No. Percentage
Sex
Male 16 67
Female 8 33
Age, yr
Median 60
Range 41–76
Race
Caucasian 15 63
African American 7 29
Other 2 8
Performance status
0 4 17
1 12 50
2 8 33
Stage
IIIA 1 4
IIIB 4 17
IV 19 79
Number of previous chemo regimens
1 14 58
2 10 42
Platinum refractory 12 50
Received prior paclitaxel 18 75
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mates of TTF and OS for the 24 patients are presented in
Figure 1.
DISCUSSION
Our study achieved the primary end point of greater
than 6-month survival in 59% of the patients enrolled in stage
I, although it is underpowered with poor precision due to the
early termination. Unacceptable hematologic toxicity resulted
in early closure of the trial which included grade 3–4 neu-
tropenia in 70% and neutropenic fever in 25% of patients who
received both celecoxib and docetaxel. Although patient
selection may have contributed to this (half of the patients
were platinum-refractory, one-third had a PS of 2), the
response and survival results are, nevertheless, comparable
with 2 other trials utilizing docetaxel plus celecoxib in ad-
vanced NSCLC. Csiki et al.31 used the same dose and sched-
ule of docetaxel and celecoxib in 56 patients and reported a
response rate of 11%, a median survival of 6 months, and a
1-year survival of 23%. Nugent et al.32 demonstrated in 39
patients a response rate of 10%, median survival of 11.3
months and 1-year survival of 48%. However, these results
are not much different than those observed with single agent
docetaxel, suggesting the addition of celecoxib did not im-
prove overall survival.4,5
Early clinical data utilizing celecoxib as an antineoplas-
tic agent seemed promising. A study by Altorki et al.33
demonstrated elevated intratumoral levels of COX-2 and
PGE2 after treatment with neoadjuvant carboplatin and pac-
litaxel, suggesting chemotherapy induced up-regulation of
COX-2. Neoadjuvant treatment with celecoxib 400 mg twice
daily plus chemotherapy substantially reduced intratumoral
PGE2 levels evaluated in the post surgical specimens, how-
ever, given the small sample size, these results could not be
correlated with survival.
Another study by Altorki et al.34 confirmed tolerability
of the combination of celecoxib, paclitaxel and carboplatin as
neoadjuvant therapy for patients with resectable NSCLC. A
dramatic reduction in tumoral PGE2 levels was noted com-
pared with control patients and results indicated celecoxib
may enhance the response of paclitaxel and carboplatin in
patients with NSCLC. Csiki et al. also reported 5 subjects
who underwent assessment of intratumoral PGE2 after ad-
ministration of celecoxib 400 mg twice daily, 4 of whom had
significant decreases in PGE2 posttherapy. This trial also
evaluated urinary PGE-M levels (the primary urinary metab-
olite of PGE2) both pre and postadministration of celecoxib.
A dramatic reduction in previously elevated urinary PGE-M
levels correlated with improvement in survival in patients
with advanced NSCLC.
Despite these compelling data that suggest COX-2 is a
valid in vivo target, COX-2 inhibition has not consistently
demonstrated enhancement of the antitumor activity of cyto-
toxics in clinical trials. Gridelli et al.35 used gemcitabine and
cisplatin with or without the COX-2 inhibitor rofecoxib in
patients with untreated advanced NSCLC and no survival
benefit was identified. A recent trial by Lilenbaum et al.36
evaluated docetaxel plus irinotecan or gemcitabine plus iri-
notecan with or without the addition of celecoxib for second-
line therapy in patients with advanced NSCLC. Survival was
actually worse in patients who received chemotherapy plus
celecoxib (median survival 6.3 months) compared with the
patients who received the chemotherapy alone (median sur-
vival 9 months). It was postulated that celecoxib may reduce
the level of prostaglandin I2 which has antitumor properties,
leading to promotion of tumor growth rather than inhibition.37
Unfortunately, efficacy and survival do not seem to
have improved with the addition of celecoxib to docetaxel
when administered to an unselected population and the mar-
row toxicity seems to have been enhanced compared with
docetaxel alone. The Lilenbaum study reported that 35% of
patients who received docetaxel/irinotecan/celecoxib demon-
strated grade 3–4 neutropenia compared with 20% who
received docetaxel/irinotecan without celecoxib. Similarly,
Csiki et al. and Nugent et al. both reported grade 3–4
neutropenia (57% and 26%, respectively) and febrile neutro-
penia (15% and 9%, respectively) as 2 of the most common
toxicities of docetaxel plus celecoxib. This is consistent with
our study which suggests a synergistic effect of docetaxel
plus celecoxib in the development of neutropenia compared
with docetaxel alone.
It is possible that COX-2 is required for marrow recov-
ery after cytotoxic chemotherapy.38 Preclinical data suggest
that chemotherapy-induced bone marrow necrosis requires an
inflammatory response to remove dead cells and debris to
maintain a proper hematopoetic milieu. Mice deficient in the
COX-2 gene demonstrated a slow marrow recovery following
administration of 5-fluorouracil compared with wild-type
mice given the same agent. Interestingly, when hemolysis
was induced in the COX-2 deficient mice, erythropoesis was
unhindered compared with the wild-type mice suggesting
COX-2 was required for repair of marrow damage, but was
not necessary for normal marrow hematopoesis.
Recently, results were presented from the Cancer and
Leukemia Group B trial 30203 that evaluated celecoxib
and/or zileuton (5-LOX inhibitor) plus standard chemother-
FIGURE 1. Intent To Treat Kaplan-Meier estimates for over-
all and time to treatment failure survival for all patients n 
24 (median overall survival, 5.7 months; median time to
treatment failure, 1.61 months).
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apy in advanced NSCLC.39 Patients received carboplatin and
gemcitabine with celecoxib, zileuton, or both and although
failure free survival and overall survival did not differ among
the three arms (or compared with historic controls), a pre-
planned analysis of COX-2 expression as a prognostic and
predictive marker demonstrated intriguing results. Patients
who did not receive celecoxib and demonstrated high intra-
tumoral expression of COX-2 by immunohistochemistry had
a worse outcome compared with patients with low expres-
sion. This confirmed retrospective studies that suggested
overexpression of COX-2 in NSCLC is a negative prognostic
factor.40 Also, patients treated with celecoxib who demon-
strated moderate or high COX-2 expression had an improve-
ment in overall survival compared with those with moderate
or high COX-2 expression who did not receive celecoxib.
Interestingly, patients with low COX-2 expression treated
with celecoxib seemed to have a worse overall survival
compared with patients who overexpressed COX-2 and re-
ceived celecoxib. In our trial, patients were not selected based
on COX-2 expression and, as Edelman et al. has suggested, a
negative effect of celecoxib in patients with low COX-2
expression may have diluted the benefit attained in the pa-
tients with moderate to high COX-2 expression.
Nonsmokers seem to have less COX-2 activity com-
pared with active and former smokers, suggesting different
dose levels would be required for adequate inhibition based
on the smoking status of the patient. With a “one size fits all”
dose of celecoxib, previous studies have shown that PGE2
production was inhibited to a greater degree in nonsmok-
ers.31,41 The preselection of NSCLC patients based on tumor
expression of COX-2 may be important to observe an anti-
tumor effect of celecoxib. Immunohistochemical analysis of
the tumor or surrogate markers of COX-2 expression such as
urinary PGE-M levels could be used prospectively to enhance
a clinical trial population most likely to respond to celecoxib.
In conclusion, our study demonstrates that celecoxib
added to docetaxel may enhance marrow toxicity and, in
unselected patients, there is no clear improvement in survival.
Evaluation of celecoxib with or without chemotherapy in
appropriately selected patients may be beneficial and war-
rants further investigation.
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